Clinical trials
Heart Failure trials in Colombia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2013 | 3 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Recruiting | 5 |
| Unknown status | 4 |
| Terminated | 3 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 5 |
| Abbott Medical Devices | 3 |
| Boehringer Ingelheim | 3 |
| Bayer | 2 |
| Universidad de la Sabana | 2 |
| Amgen | 1 |
| Ancora Heart, Inc. | 1 |
| AstraZeneca | 1 |
| CSL Behring | 1 |
| Clinica Cardio VID | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heart Failure | 34 |
| Cardiovascular Diseases | 3 |
| Coronary Artery Disease | 2 |
| Stroke | 2 |
| Acute Coronary Syndrome | 1 |
| Atherosclerosis | 1 |
| Atrial Fibrillation | 1 |
| Cardiomyopathies | 1 |
| Chagas Cardiomyopathy | 1 |
| Chagas Disease | 1 |
Trials
Showing 51 to 34 of 34. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.